Cell Signaling Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cell Signaling Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The cell signaling market is expected to register a CAGR of 9.8% over the forecast period

The COVID-19 pandemic had a profound impact on the market studied. A study published in the journal News Medical, "SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells" in October 2020 stated that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus without the rest of the viral components. As this signaling mechanism is potentially linked to worse outcomes in this situation, these findings could indicate new targets for the development of therapeutic agents. Thus, the high utility of cell signaling models for research about COVID-19 and respiratory diseases has offered significant growth opportunities to the market.

The significant factors for the growth of the cell signaling market include the rising incidence of chronic diseases, increased funding for cell-based research, and technological advancements in cell-based research instruments. For instance, in April 2022, as per the national library of medicine 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States 2021. There is rising funding for cell-based research across the world. For instance, according to the data available on the portal for the National Institutes of Health (NIH), an estimated USD 45 billion was granted for stem cell research in the fiscal year 2021. Similar in March 2020, increments in funding grants were observed for research of embryonic stem cells and induced pluripotent stem cells. Similar positive trends in the increment of fund grants have been observed in the European Union for cell-based research. Consequently, the increasing participation of the government in the development of cell-based research, in the form of incremental funding, is expected to drive the growth of the market studied. Other factors contributing to the growth of the market studied include the increasing incidence of chronic diseases and technological advancements in cell-based research instruments.

However, the high cost of cell signaling systems and ethical issues related to embryonic stem cell signaling research are likely to hinder the market growth.

Key Market TrendsThe AKT Signaling Pathway Segment is Expected to Register Good Growth Over the Forecast Period

The AKT signaling pathway, also known as the survival pathway, is responsible for the increased proliferation, loss of apoptosis signaling, and cell growth. The AKT signaling pathway is the most commonly dysregulated pathway in the most prevalent forms of cancer. A number of drugs have been designed based on the rationale that inhibition of AKT pathway, could help in achieving therapeutic results. A number of drugs based on AKT signaling are currently in various stages of clinical trials.

In the treatment of advanced-stage COVID-19 patients, AKT is found as a potential therapeutic target. Its inhibition will potentially suppress the cytokine storm, fibroproliferation, pathological inflammation, and platelet activation associated with COVID-19. It also promotes resolution and prevents scarring in injured lungs. As per the study published "AKT a viable option to treat advanced-stage COVID-19 patients" in 2020, pharmacological inhibition of AKT has also been reported to inhibit angiotensin-converting enzyme 2 (ACE2) expression, a receptor for the virus entry into the lung cells, and targeting AKT for COVID-19 looks like a viable option.

Over the forecast period, this market is expected to grow, as commercial diagnostic tests are expected to emerge based on down-regulation of the AKT pathway.

North America is Expected to Dominate the Market Over the Forecast Period

North America holds a significant share of the cell signaling market and is expected to show a similar trend over the forecast period, without significant fluctuations. The cell signaling market is expected to witness numerous growth opportunities during the pandemic, with cell signaling pathways being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Most of the major players have been involved in R&D activities regarding cell signaling pathways. The mortality in most COVID-19 patients is due to the presence of a cytokine storm, which is induced by the virus. The excessive production of these proinflammatory cytokines leads to acute respiratory distress syndrome aggravation and widespread tissue damage, which results in multi-organ failure and death. Thus, targeting cell signaling pathways such as cytokines during the management of COVID-19 may lead to the reduction of the mortality rate and improved outcomes. This is likely to have a positive impact on the market studied.

In the United States, for the fiscal year 2021, USD 575 million was granted by the federal government for the National Cancer Institute (NCI) budget for breast cancer research, USD 225 million for colorectal cancer research, and USD 250 million for leukemia. Additionally, the estimates available on the National Institute of Health Portal for stem cell-based research indicate a cumulative funding budget of more than USD 3 billion for research in various fields of stem cell applications. The need for cell signaling in cancer research plays a vital role in the progressive growth of the cell signaling market in the United States. The growing funding in cancer research and stem cell research are directly causing an increase in cell signaling research, particularly in the United States. The increasing trend of increment in research funding is expected to lead to the growth of the market studied in the United States.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are Danaher Corporation (Beckman Coulter Inc.), Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Merck KGaA, PerkinElmer Inc., Promega Corporation, Qiagen NV, and Thermo Fischer Scientific Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.